[123I]-metaiodobenzylguanidine imaging findings and outcome in patients with metastatic neuroblastoma

Background: 123I-Metaiodobenzylguanidine ([123I]mIBG) is the agent of choice to assess for presence metastases and therapy response in patients with neuroblastoma.Aim: To [123I]mIBG scan results outcome stage 4 neuroblastoma at our institution.Setting: Red Cross War Memorial Children’s Hospital.Methods: A retrospective review baseline follow-up scans who presented between January 2001 May 2015. The clinical follow up extended until October 2019. association post-induction Curie score (CS) overall survival (OS) were assessed.Results: Thirty-four disease included. Twenty-two (65%) died. median age diagnosis survivors was 15.5 months vs 39 those died (Kruskal Wallis c2 = 4.63, p 0.03). Neither CS nor predict or duration survival. OS a ≤ 12 19 26 months, 0.13. 2 28 0.66.Conclusion: In this study, baseline, reduction did not neuroblastoma. Factors such as small patient numbers, less intensive treatment regimes, possible poorly dedifferentiated have been identified finding.Contribution: contrast international studies South African setting where vast majority are treated OPEC/OJEC (vincristine [O], cisplatin [P], etoposide [E], cyclophosphamide [C] carboplatin [J]) chemotherapy.